Recursion Pharmaceuticals, Inc. (RXRX)
3.245
-0.26
(-7.29%)
USD |
NASDAQ |
Aug 24, 16:00
3.26
+0.02
(+0.46%)
After-Hours: 20:00
Recursion Pharmaceuticals Enterprise Value : 1.385B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 1.385B |
| August 20, 2026 | 1.300B |
| August 19, 2026 | 1.385B |
| August 18, 2026 | 1.166B |
| August 17, 2026 | 1.177B |
| August 14, 2026 | 1.203B |
| August 13, 2026 | 1.284B |
| August 12, 2026 | 1.273B |
| August 11, 2026 | 1.305B |
| August 10, 2026 | 1.273B |
| August 07, 2026 | 1.235B |
| August 06, 2026 | 1.214B |
| August 05, 2026 | 1.209B |
| August 04, 2026 | 1.284B |
| August 03, 2026 | 1.214B |
| July 31, 2026 | 1.118B |
| July 30, 2026 | 1.139B |
| July 29, 2026 | 1.102B |
| July 28, 2026 | 1.145B |
| July 27, 2026 | 1.123B |
| July 24, 2026 | 1.097B |
| July 23, 2026 | 1.123B |
| July 22, 2026 | 1.107B |
| July 21, 2026 | 1.161B |
| July 20, 2026 | 1.059B |
| Date | Value |
|---|---|
| July 17, 2026 | 1.089B |
| July 16, 2026 | 1.129B |
| July 15, 2026 | 1.284B |
| July 14, 2026 | 1.300B |
| July 13, 2026 | 1.278B |
| July 10, 2026 | 1.417B |
| July 09, 2026 | 1.524B |
| July 08, 2026 | 1.502B |
| July 07, 2026 | 1.567B |
| July 06, 2026 | 1.631B |
| July 02, 2026 | 1.545B |
| July 01, 2026 | 1.476B |
| June 30, 2026 | 1.476B |
| June 29, 2026 | 1.370B |
| June 26, 2026 | 1.280B |
| June 25, 2026 | 1.185B |
| June 24, 2026 | 1.126B |
| June 23, 2026 | 1.089B |
| June 22, 2026 | 1.100B |
| June 18, 2026 | 1.126B |
| June 17, 2026 | 1.063B |
| June 16, 2026 | 1.100B |
| June 15, 2026 | 1.158B |
| June 12, 2026 | 1.084B |
| June 11, 2026 | 1.084B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Twist Bioscience Corp. | 9.051B |
| Absci Corp. | 1.441B |
| Novavax, Inc. | 1.051B |
| Editas Medicine, Inc. | 337.09M |
| Dyne Therapeutics, Inc. | 3.659B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -131.00M |
| Revenue (Quarterly) | 7.67M |
| Total Expenses (Quarterly) | 138.68M |
| EPS Diluted (Quarterly) | -0.246 |
| Gross Profit Margin (Quarterly) | -202.4% |
| Profit Margin (Quarterly) | -1.71K% |
| Earnings Yield | -31.94% |
| Normalized Earnings Yield | -31.94 |